308 related articles for article (PubMed ID: 32386596)
21. A Call for Systematic Research on Solute Carriers.
César-Razquin A; Snijder B; Frappier-Brinton T; Isserlin R; Gyimesi G; Bai X; Reithmeier RA; Hepworth D; Hediger MA; Edwards AM; Superti-Furga G
Cell; 2015 Jul; 162(3):478-87. PubMed ID: 26232220
[TBL] [Abstract][Full Text] [Related]
22. The dTAG system for immediate and target-specific protein degradation.
Nabet B; Roberts JM; Buckley DL; Paulk J; Dastjerdi S; Yang A; Leggett AL; Erb MA; Lawlor MA; Souza A; Scott TG; Vittori S; Perry JA; Qi J; Winter GE; Wong KK; Gray NS; Bradner JE
Nat Chem Biol; 2018 May; 14(5):431-441. PubMed ID: 29581585
[TBL] [Abstract][Full Text] [Related]
23. SLC transporters as therapeutic targets: emerging opportunities.
Lin L; Yee SW; Kim RB; Giacomini KM
Nat Rev Drug Discov; 2015 Aug; 14(8):543-60. PubMed ID: 26111766
[TBL] [Abstract][Full Text] [Related]
24. Systematic in silico discovery of novel solute carrier-like proteins from proteomes.
Gyimesi G; Hediger MA
PLoS One; 2022; 17(7):e0271062. PubMed ID: 35901096
[TBL] [Abstract][Full Text] [Related]
25. Solute carriers (SLCs) identified and characterized from kidney transcriptome of golden mahseer (Tor putitora) (Fam: Cyprinidae).
Barat A; Sahoo PK; Kumar R; Pande V
Comp Biochem Physiol B Biochem Mol Biol; 2016 Oct; 200():54-61. PubMed ID: 27287540
[TBL] [Abstract][Full Text] [Related]
26. Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates.
Mandíková J; Volková M; Pávek P; Česnek M; Janeba Z; Kubíček V; Trejtnar F
Toxicology; 2013 Sep; 311(3):135-46. PubMed ID: 23856525
[TBL] [Abstract][Full Text] [Related]
27. Mammalian zinc transporters.
Liuzzi JP; Cousins RJ
Annu Rev Nutr; 2004; 24():151-72. PubMed ID: 15189117
[TBL] [Abstract][Full Text] [Related]
28. Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay.
Foley CA; Potjewyd F; Lamb KN; James LI; Frye SV
ACS Chem Biol; 2020 Jan; 15(1):290-295. PubMed ID: 31846298
[TBL] [Abstract][Full Text] [Related]
29. Analysis and update of the human solute carrier (SLC) gene superfamily.
He L; Vasiliou K; Nebert DW
Hum Genomics; 2009 Jan; 3(2):195-206. PubMed ID: 19164095
[TBL] [Abstract][Full Text] [Related]
30. Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules.
Okuhira K; Shoda T; Omura R; Ohoka N; Hattori T; Shibata N; Demizu Y; Sugihara R; Ichino A; Kawahara H; Itoh Y; Ishikawa M; Hashimoto Y; Kurihara M; Itoh S; Saito H; Naito M
Mol Pharmacol; 2017 Mar; 91(3):159-166. PubMed ID: 27965304
[TBL] [Abstract][Full Text] [Related]
31. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.
Qi SM; Dong J; Xu ZY; Cheng XD; Zhang WD; Qin JJ
Front Pharmacol; 2021; 12():692574. PubMed ID: 34025443
[TBL] [Abstract][Full Text] [Related]
32. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
34. Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease.
Schumann T; König J; Henke C; Willmes DM; Bornstein SR; Jordan J; Fromm MF; Birkenfeld AL
Pharmacol Rev; 2020 Jan; 72(1):343-379. PubMed ID: 31882442
[TBL] [Abstract][Full Text] [Related]
35. Impact of Solute Carrier Transporters in Glioma Pathology: A Comprehensive Review.
Anagnostakis F; Kokkorakis M; Markouli M; Piperi C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298344
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase.
Degorce SL; Tavana O; Banks E; Crafter C; Gingipalli L; Kouvchinov D; Mao Y; Pachl F; Solanki A; Valge-Archer V; Yang B; Edmondson SD
J Med Chem; 2020 Sep; 63(18):10460-10473. PubMed ID: 32803978
[TBL] [Abstract][Full Text] [Related]
37. The solute carrier families have a remarkably long evolutionary history with the majority of the human families present before divergence of Bilaterian species.
Höglund PJ; Nordström KJ; Schiöth HB; Fredriksson R
Mol Biol Evol; 2011 Apr; 28(4):1531-41. PubMed ID: 21186191
[TBL] [Abstract][Full Text] [Related]
38. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of 29 novel atypical solute carriers of major facilitator superfamily type: evolutionary conservation, predicted structure and neuronal co-expression.
Perland E; Bagchi S; Klaesson A; Fredriksson R
Open Biol; 2017 Sep; 7(9):. PubMed ID: 28878041
[TBL] [Abstract][Full Text] [Related]
40. Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders.
Roberts BL; Ma ZX; Gao A; Leisten ED; Yin D; Xu W; Tang W
ACS Chem Biol; 2020 Jun; 15(6):1487-1496. PubMed ID: 32255606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
